Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling
- 8 November 2019
- journal article
- research article
- Published by Elsevier BV in The American Journal of the Medical Sciences
- Vol. 359 (2), 123-129
- https://doi.org/10.1016/j.amjms.2019.11.001
Abstract
No abstract availableKeywords
Funding Information
- Wuhan Medical Research (WZ18Z02, WZ18Q04)
This publication has 23 references indexed in Scilit:
- The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challengesChinese Journal of Cancer, 2015
- The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT‐TCF pathway responses in human cancerEMBO Molecular Medicine, 2014
- Bioenergetic Analysis of Ovarian Cancer Cell Lines: Profiling of Histological Subtypes and Identification of a Mitochondria-Defective Cell LinePLOS ONE, 2014
- Therapeutic strategies in epithelial ovarian cancerJournal of Experimental & Clinical Cancer Research, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cellsBlood, 2010
- Inhibitors Directed towards Caspase-1 and -3 Are Less Effective than Pan Caspase Inhibition in Preventing Renal Proximal Tubular Cell ApoptosisNephron Experimental Nephrology, 2004
- Pharmacological effects of ivermectin, an antiparasitic agent for intestinal strongyloidiasis: its mode of action and clinical efficacy.Folia Pharmacologica Japonica, 2003
- Akt, a Pleckstrin Homology Domain Containing Kinase, Is Activated Primarily by PhosphorylationOnline Journal of Public Health Informatics, 1996
- Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulusEuropean Journal of Clinical Pharmacology, 1996